DOE senior scientist Yi Shouliang leaves US for China
scientist Yi Shouliang has returned to
China to take up a new role at
Sichuan University , after permanently leaving the US where he previously worked at the federal government's Department of Energy.
Advertisement
The career decision, which follows this year's escalating
Sino-US tensions , saw him leave his
academic role as adjunct professor at the University of Pittsburgh after less than 12 months and dissolve his commercial ventures.
Previously, he was a principal scientist and project leader at the DOE's National
Energy Technology Laboratory (NETL) where he focused on the Water-Energy Programme but resigned in June 2023 after five years at the helm.
He then founded American Sustainable Membrane Technology LLC, serving as its CEO.
At NETL, Yi's research focused on developing novel membranes and adsorption materials for the Carbon Capture, Utilisation, and Storage (CCUS) programme and water management initiatives.
Senior scientist Yi Shouliang has left the US where he was working as an adjunct professor at the University of Pittsburgh to return to China. Photo: TNS
The circumstances surrounding his departure remain undisclosed and there are no listed records of Yi as a chief researcher on the DOE and NETL's official websites, despite his lengthy tenure. Currently, his name only appears in patent filing and project proposals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
5 days ago
- RTHK
Settlement reached over Covid-19 vaccines
Settlement reached over Covid-19 vaccines The Pfizer-BioNTech vaccine was the first mRNA vaccine approved for use and the first Covid vaccine to receive approval in the West. File photo: RTHK American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac US$740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said on Friday. The royalties would amount to a "single-digit" percentage on sales of Covid-19 vaccines in the United States, CureVac said. The German firm added that it would grant Pfizer and BioNTech the non-exclusive licence to make and sell mRNA-based Covid and flu products in the United States. GSK, which has worked with CureVac since 2020 to develop mRNA vaccines for infectious diseases, said that it would receive US$370 million as well as a 1 percent royalty on US sales of flu, Covid and "related combination mRNA vaccine products". CureVac sued German rival BioNTech in 2022, arguing that it had infringed patents relating to mRNA technology in making its blockbuster Comirnaty coronavirus vaccine in collaboration with Pfizer. Unlike traditional vaccines that contain some form of the dead or inactivated target virus, mRNA vaccines contain genetic materials that instruct human cells to make proteins typical of the targeted virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than conventional vaccines. The Pfizer-BioNTech vaccine was the first mRNA vaccine approved for use and the first Covid vaccine to receive approval in the West. CureVac's own efforts to make an mRNA-based Covid vaccine during the pandemic did not come to fruition. The deal brings the dispute between CureVac and BionNTech to an end ahead of the planned acquisition of CureVac by BioNTech, announced in June. CureVac and BioNTech are still locked in legal disputes in Germany but CureVac said the deal "set a framework for resolving ongoing patent disputes outside the US". In March, a German court sided with American pharmaceutical firm Moderna in its claim that BioNTech and Pfizer had broken one of its patents in making its Covid-19 vaccine. (AFP)
South China Morning Post
06-08-2025
- South China Morning Post
How China has taken lead in rare earths race
How China has taken lead in rare earths race Rare earths are needed for everything from consumer electronics to electric vehicles, wind turbines and fighter jets. In this four-part series, we look at the race for these critical minerals, how China has taken a commanding role in the industry and what the US is doing to battle back.
South China Morning Post
03-08-2025
- South China Morning Post
Brain scan predicts dementia risk by reading brain's ‘hidden ageing clock'
This is the 68th instalment in a series on dementia , including the research into its causes and treatment, advice for carers, and stories of hope. Advertisement A team of scientists from Duke University and Harvard University in the US, and the University of Otago in New Zealand, has just unveiled a new MRI-based tool that reads the brain's 'hidden ageing clock'. The DunedinPACNI takes the front of its name from the Dunedin Study, a long-running health research project in New Zealand that began in 1972, while PACNI stands for Pace of Ageing Calculated from NeuroImaging. It has been tracking 1,037 babies born in Dunedin from birth, continuing through their entire lives. Think of it as a 50-year time-lapse study on human health; it is often called 'the world's most detailed study of human development'. The DunedinPACNI uses an MRI-based tool like this MRI machine to read the brain's 'hidden ageing clock'. Photo: Shutterstock The Dunedin Study's value comes from the fact that it follows the same people over time. Researchers regularly collect detailed data on all aspects of their health – physical, mental and brain health, lifestyle, relationships, and even genetics. Advertisement
